Hefei Tiangang Immunotherapy

Hefei Tiangang Immunotherapy is a clinical-stage biotechnology company focused on the discovery and development of next-generation cancer immunotherapies, with a particular emphasis on Natural Killer (NK) cell checkpoints. Founded by experts from the University of Science and Technology of China, the company leverages a proprietary platform to identify novel immune checkpoints and develop high-affinity monoclonal and bispecific antibodies. Its lead programs target the TIGIT and KIR3DL3 pathways, aiming to overcome resistance to current PD-1/PD-L1 therapies. The company is headquartered in Hefei, China, and maintains a robust pipeline of biologics designed to activate both innate and adaptive immunity against solid tumors.